Study finds safer, more efficient medication for hepatitis B treatment

Patients with hepatitis B who did not respond to lamivudine therapy had a better virological response after switching to entecavir for a year. Continuing the drug for an additional year led to even more clinical improvement without significant side effects, according to a new study in the July issue of Hepatology.

Read the whole article on Physorg

More from Physorg